Group 2 and 3 ABC-transporter-dependent capsular K-loci contribute significantly to variation in the estimated invasive potential of *Escherichia coli*

Rebecca A. Gladstone[1], Maiju Pesonen[2], Anna K. Pöntinen[1], Tommi Mäklin[3], Neil MacAlasdair[1,4], Harry Thorpe[1], Yan Shao[4], Sudaraka Mallawaarachchi[1,5,6], Sergio Arredondo-Alonso[1], Benjamin J. Parcell[7], Jake David Turnbull[8], Gerry Tonkin-hill[1,5,6,9], Pål J. Johnsen[10], Ørjan Samuelsen[11], Nicholas R. Thomson[4,12], Trevor Lawley[4], Jukka Corander[1,3,4]

Department of Biostatistics, University of Oslo, Oslo, Norway

Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway

Department of Mathematics and Statistics, University of Helsinki, Helsinki, Finland

Parasites and Microbes, Wellcome Sanger Institute, Hinxton, UK

Peter MacCallum Cancer Centre, Melbourne, Australia

Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia

Division of Population Health and Genomics, School of Medicine, University of Dundee, Dundee, UK

The National Collection of Type Cultures, Culture Collections, UK Health Security Agency

Department of Microbiology and Immunology, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia

Department of Pharmacy, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway

Norwegian National Advisory Unit on Detection of Antimicrobial Resistance, Department of Microbiology and Infection Control, University Hospital of North Norway, Tromsø, Norway

London School of Hygiene and Tropical Medicine, London, WC1E 7HT, United Kingdom

Corresponding authors: Rebecca A. Gladstone (r.a.gladstone@medisin.uio.no), Jukka Corander (jukka.corander@medisin.uio.no)

Funding: The project was funded by the Trond Mohn Foundation (grant identifier TMS2019TMT04 to A.K.P., R.A.G., Ø.S., P.J.J., and J.C.). The presented work has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie Actions (grant No. 801,133 to S.A.-A. and A.K.P.), from Wellcome Trust (grant no. 220540/Z/20/A to YS, TL) and has also been supported by the European

Research Council (grant No. 742158 to J.C.). This work was supported, in part, by the Bill &
Melinda Gates Foundation INV-025304. The conclusions and opinions expressed in this work
are those of the author(s) alone and shall not be attributed to the Foundation. Under the grant
conditions of the Foundation, a Creative Commons Attribution 4.0 License has already been
assigned to the Author Accepted Manuscript version that might arise from this submission.
Please note works submitted as a preprint have not undergone a peer review process.

Abstract

The major opportunistic pathogen *Escherichia coli* is the largest cause of antimicrobial resistance (AMR) associated infections and deaths globally. Considerable antigenic diversity has been documented in Extra-intestinal pathogenic *E. coli* (ExPEC), however, phenotypic capsular (K) typing has fallen out of use. Recent systematic genomic surveys have provided an opportunity to compare colonisation and bloodstream infection frequencies to quantify the relative invasive potential of capsules across different ExPEC lineages. We assembled and curated an *in silico* capsular locus typing database for group 2 and group 3 K-loci from >20,000 genomes and applied it to carriage and disease cohorts to investigate capsule epidemiology. Several widely circulating K-loci have estimated odds ratios of >7 for being found in bloodstream infections compared with carriage. The relative invasive potential differed markedly between lineages, and notably, even between subclades of the multidrug-resistant ST131 clone. We determined that insertion sequence elements contribute to the evolutionary dynamics of group 2 and group 3 K-loci by importing new capsular genes. The level of capsule diversity was positively correlated with a higher rate of homologous recombination per lineage, likely a consequence of faster adaptation of their antigenic repertoire. Our investigation highlights several capsules and lineages that contribute disproportionately to invasive ExPEC disease, some of which are also associated with high levels of AMR. These results have generated new insights into capsule epidemiology and have significant translational potential, including improved ExPEC diagnostics, personalised therapy options, and the ability to build predictive regional risk maps by combining genomic surveys with demographic and patient frailty data.

Introduction

Capsules are major virulence determinants in bacterial pathogens. They have many critical roles, including shielding bacteria from the immune system, influencing the ability to cause invasive infections and acting as a barrier to antimicrobials. They can also impact DNA exchange, phage predation, and plasmid uptake, all of which have evolutionary underpinnings. Bacterial capsular polysaccharide antigens are often well-studied and used as a central component of disease surveillance and as effective vaccine targets, including for *Streptococcus pneumoniae*, *Haemophilus influenzae* and *Neisseria meningitidis*[1]. Whilst *Escherichia coli* is the leading cause of bacterial bloodstream infections (BSIs) globally, little is known about the current diversity of capsules found in extra-intestinal (ExPEC) infections. *E. coli* has additionally been shown to represent the species causing the highest burden of antimicrobial-resistant BSI-associated deaths, making vaccine development and improved diagnostics an even greater priority[2]. Capsules are generally considered good targets for translational research to develop new antimicrobials, phage therapy and vaccines. Although some *E. coli* capsular (K)-types mimic vertebrate glycoconjugates, hindering vaccine development,[3,4] their true prevalence in contemporary disease has not been determined in large, unbiased disease cohorts. There have also been early *in vivo* successes demonstrating the potential of phage therapy in invasive infections[5].

Over 80 *E. coli* K-types can be identified with traditional phenotypic capsular typing using a set of antisera. However, this method is labour-intensive and no longer in general use. Unlike other important *E. coli* antigens, such as O and H-types[6], no genotypic method exists for typing the capsular loci encoding the K-types, and a lack of paired capsular phenotype and genotype data has hindered its development. *E. coli* capsular K-loci have been classified into four groups based on whether they are *wzy*-dependent (groups 1 and 4) or *kps*-ABC-transporter dependent (groups 2 and 3) and further subdivided by the genetic organisation of the capsule locus[7,8]. Small collections of isolates have highlighted associations between the four capsular groups, phylogroups and disease types. The ExPEC-associated B2, D, and F phylogroups almost always carry group 2 (G2) capsules[9]. Conversely, the phylogroups A, B1, C and E are mainly associated with intestinal carriage, and these commonly carry group 1 or 4 capsules, which are less common in invasive disease[9]. The ExPEC-associated G2 and group 3 (G3) K-loci have conserved capsular polysaccharide (*kps*) genes found in Region 1 involved in assembly and export, and Region 3 involved in transport. These genes flank the capsular-determining genes

in Region 2 and encode, for example, glycosyl transferases and sugar synthetases. G2 and G3

K-loci are found near *serA* in the chromosome; however, recently, a subgroup of G3 K-loci have

also been observed on plasmids[10]. The conserved gene content and organisation of G2 and G3

loci make them an ideal candidate for *in silico* typing. *In silico* methods for the broader

assessment of capsule loci across bacterial families and species have already increased our

understanding of these important antigens, even in the absence of comprehensive phenotypic

data, by taking a capsular gene-based approach [11–13]. A G2 and G3 *E. coli* typing scheme will

complement the considerable previous work on phenotypes and structures to stimulate further

study of *E. coli* K-types[14], as has been demonstrated for typing schemes in other species[13,15,16].

Systematically collected data on capsule prevalence can allow the estimation of their relative

invasive potential. This has been instrumental in identifying those capsules with the greatest

potential to cause invasive disease in multiple species, especially the pneumococcus, providing

a ranking for prioritising inclusion in vaccines and modelling optimal polyvalent vaccine

formulations.[17–22] This epidemiological approach leverages measured frequencies in

colonisation and observed disease cases to calculate an odds ratio that indirectly captures the

relationship between exposure and the subsequent manifestation of disease cases in a

population[23,24], which has been further employed in the estimation of R0 for *E. coli* strains[25].

Here, we catalogue the substantial diversity of *E. coli* G2 and G3 capsular loci, present their

prevalence in BSIs, UTIs and carriage cohorts, and quantify the relative invasive potential

associated with them. Furthermore, we investigate the links between capsule diversity and DNA

exchange in homologous recombination, insertion sequence elements and plasmids. Our

results highlight key K-loci encoding capsular antigens that require renewed scrutiny and

attention in translational efforts to reduce the future public health burden of *E. coli* invasive

disease.

118 Results

By investigating a collection of >20,000 high-quality *E. coli* genomes, we observed 90 unique

G2 (n=68) and G3 (n=22) ABC-transporter-dependent capsular (K) loci, based on capsular

locus gene presence-absence patterns. Eighty percent of the known G2 and G3 phenotypic K-

types are represented here by phenotype-genotype paired data, yet known phenotypes only

represent 34% of the 90 K-loci observed to have unique capsular gene sets. Furthermore, for 11

K-loci without a known phenotype that were observed in Norwegian BSIs we were able to

confirm a K+ phenotype with a positive precipitate with Cetavlon and that they were negative for

known K antigens representing putatively novel K-types. The 90 curated K-loci were used to

create a G2 and G3 *in silico E. coli* K-typing reference database available at

https://github.com/rgladstone/EC-K-typing, compatible with the species agnostic bacterial

capsular loci typing tool Kaptive[26]. We K-locus typed assemblies from several systematic

studies of infections, including: 1) large longitudinal genomic surveys of bloodstream infections

(BSIs) from Norway[27] and the UK[24,28,29], 2) two urinary tract infection (UTI) surveys from Norway

and France[30], 3) UTIs with specific resistance profiles from the USA[31], and 4) two collections of

invasive isolates from neonates collected in low and middle-income countries (LMICs).[32,33] In

addition, K-locus typing of assemblies from infant-mother gut metagenomic surveys in the

UK[23,34] and from traditional culture picks (France[35]) provided information on K-types in

asymptomatic colonisation. As over 65% of K-loci did not pair with the known phenotypic K-

types described in the previous century, phenotypes can be added retrospectively to each K-

locus in the public database as data become available. The KL designations reported here are

determined algorithmically and consequently do not mirror the phenotypic K-type numbering.

Throughout this manuscript, we will report the inferred phenotypic K-type (e.g, K1) for a given K-

locus (KL) genotype when available. Where no phenotypic K-type currently exists for a K-locus,

a numerical KL designation (e.g. KL5) will be used instead.

143 K-locus epidemiology

European BSIs[24,27–29] are predominantly caused by strains with a G2 or G3 capsule (81.3%);

among these, G2 dominated, and only a minority had G3 loci (3.5%). The vast majority of BSI

isolates in phylogroups B2 (94.2%), D (84.1%), and F (94.6%) had G2 K-loci, and isolates with

G3 K-loci were mostly found in phylogroups B2, D and A. The top five K-types in European BSIs

were K1, K5, K52, K2, and K14 (Fig. 1). These common K-types accounted for over 50% of

BSIs (UK[24,28,29], Norway[27]) and UTIs (Norway[30], France[30]). Whilst G2 and G3 K-loci were far less

common in asymptomatic colonisation in Europe (55.4%)[23,34,35], K1 and K5 were still amongst

the most common colonising G2-G3 K-types. Notably, G2 and G3 loci were much less common

(53.9%) in invasive neonatal infections in LMICs[32,33] (Fig. 1), a stark contrast to the 95% of UK

BSIs in children <1 year old that were G2 or G3.

Figure 1. K-type prevalence across different collections. Published genomic collections were K-typed [23,24,27–35]. The top 5 K-types

in each collection are annotated. Isolates that were *kps* negative and do not contain group 2 or 3 K-loci are classified as non-G2-G3.

The estimated relative invasive potential of K-types

Using a mixed-effect model for UK isolates from carriage and BSIs, we estimated the contributions of each K-locus and lineage to the relative invasive potential (Figure 2). We determined that K52 had the highest invasive potential (OR=11.6, 95% CI: (5.3-25.4), p<0.0001) among the 18 most common K-loci in comparison to the average untypeable isolate (*i.e.* genomes without the G2-G3 *kps* genes). K14 and K100 had the second and third highest invasive potentials, respectively (OR=8.9 [3.7-21.7], OR=7.2 [2.6-20.0]). The lineage-specific odds of K100 being found in BSIs were estimated to vary within CC131 between 5.42 (CC131 clade A) and 69.80 (CC131 clade C2). There was also substantial variation in the lineage random effect estimates between CC131 subclades B and C despite sharing the same O-H type. The odds ratios for the widely studied K-types K1, K2, and K5 were ranked 12th, 5th, and 6th, respectively. These three types nevertheless had an OR significantly greater than one, demonstrating their greater invasive potential compared to untypeables. Conversely, K3 had the lowest invasive potential of 0.82 [0.2-2.7]. These findings suggest considerable variability in the propensity of K-type and lineage to cause infection, similar to previously established epidemiological findings for the pneumococcus.

We considered the burden of *E. coli* BSI by age and sex due to immunosenescence in the elderly and a higher burden of UTIs in younger women. Patient age group and sex data were available for n=1802 UK BSI isolates, we observed in an exploratory analysis (Supplementary Figure 1) that K1 was overrepresented in the <1 year (p=0.0090) and 40-49 years (p=0.0072) age groups compared to the collection as a whole, although after adjusting for multiple testing on all common age-K-type combinations these were no longer significant. We observed some sex differences in the proportion of BSIs. CC95-K1, but not K1 overall, was significantly enriched in females (adjusted p=0.013), and K52, predominantly found in the uropathogenic CC69, was observed in females in every decade of life but only occurred in older men aged ≥50, making it significantly overrepresented in females (adjusted p<0.0001), presumably due to disease progression from urinary tract infections. This may drive the general observation that the proportion of BSIs in the 1-59 age group was significantly higher for females (60%) than males (40%, p<0.0001), but was approximately even across the entire life course (females 52%, males 48%).

Group 2 K-loci association with *E.coli* and the ExPEC pathotype

E. coli G2 Region 1 and 2 *kps* genes are not often found in other species. In a published

collection of 661,000 assemblies[36], only 11,737 were positive for the highly conserved and

essential *kpsF* gene (1kb) at 90% kmer identity. These were nearly exclusively *E. coli* (99.0%,

11623/11737). Outside *E. coli*, *kpsF* was most commonly observed in *Salmonella enterica*

subspecies enterica (n=69), *Klebsiella pneumoniae* (n=17) and *Staphylococcus aureus* (n=11).

Using a published pangenome of ~7,500 *E. coli*[37], we assessed the pathotype association for

G2. ExPECs accounted for 85.8% (1590/1853) of the *kpsF*-positive isolates with pathotype

information, and non-ExPEC pathotypes accounted for 97.5% (3647/3741) of the *kpsF*-negative

isolates. Shiga toxin-producing *E. coli* (STEC) accounted for the majority of non-ExPEC

pathotypes positive for *kpsF* (90.5%, 238/263), and these STEC were found in multiple

lineages, including sequence types (ST)442, ST10, ST25, ST504 and ST675.

K-loci in major MDR lineages

The globally disseminated multidrug-resistant (MDR) lineage corresponding to the clonal

complex (CC)131 is known to have two dominant O-H types. However, we observed at least 17

different K-loci that have been introduced into CC131, highlighting the rapid capsule

diversification in this lineage (Fig. 3A). The ancestral K-type for the B/C clades is K5

(n=207/453) and K100 in clade A (n=80/104). Other K-loci found with considerable prevalence

in CC131 BSIs include: K2 (n=66/557), K14 (n=30/557) and KL44 (n=20/557), all of which were

estimated to have been acquired between 1980 and 2000. In total, K2 was acquired eight times

independently across the lineage. Interestingly, KL44 in CC131 is an example of a K-locus with

an atypical architecture, where Region 1 is immediately followed by Region 3, and Region 2 is

at the end of the locus. Its acquisition was often followed by subsequent fragmentation and

complete G2 loss events.

In another globally distributed MDR ExPEC lineage, CC69, we observed 11 O-types, 9 H-types

and 23 K-types. O diversity in CC69 was higher than in CC131 (Simpson's Diversity Index (SDI)

CC69: 0.66, CC131: 0.39), but is still less than CC69 K-locus diversity (SDI: 0.76). K-loci

belonging to G2, atypical-G2 and G3 are all found in this lineage (Fig. 3B). The most common

K-locus was K52 (39.5%, 163/413), which had the highest estimated invasive potential (Fig. 2).

Switches from K52 to the unrelated atypical KL13 occurred three separate times between 1992

and 2003.

Figure 3. Diversity of K-loci across the clades of CC131 and CC69 from Norwegian and UK BSIs. Major capsule switch events are indicated with a dashed line from the relevant nodes with the time to the most recent common ancestor and confidence intervals. A) The four major CC131 clades are labelled in column one. The major O-H types are displayed in column 2 and the K-type in column 3. B). The major CC69 O-H types are colour-coded in column 1, K-type in column 2 and the K-group in column 3. The adjacent key displays the major O-H and K-types. Where the K-phenotype is unknown, the K-locus (KL) is presented. Fully annotated interactive phylogenies are available at https://microreact.org/project/cc131-bsac-norm and https://microreact.org/project/cc69-bsac-norm

K-locus evolution

Whilst K diversity measured by Simpson's Diversity index was higher than O or H diversity in over half of the lineages observed in BSIs, lineages varied greatly in their K-type diversity (Fig. 4A), suggesting differing evolutionary processes. Indeed, the number of K-loci in a lineage was correlated with the r/m (recombination to mutation ratio) of that lineage, even when controlling for the lineage diversity by using the recombination-free median mutational pairwise distance (MMD, R^2=0.95, p<0.0001, Fig. 4B). There was no correlation between r/m and MMD (R^2=-0.35, p=0.3). The trend remained significant with the exclusion of CC69 (R^2=0.75, p=0.02), but not after excluding the two most recombinogenic lineages CC69 and CC131, though the association remained positive (R^2=0.47, p=0.2). In the top four most common lineages in BSIs (CC73, CC95, CC69 and CC131), the *kps*-locus is a clear recombination hotspot, with the exception of CC95, which only expresses K1. Highly recombinogenic lineages could contribute to the discovered changes in the K-locus genetic architecture, including the observed atypical K-loci.

Figure 4. A) Simpson's diversity index (1-D) for the richness and evenness of K-types within lineages and of lineages within a K-type. B) Pearson correlation between the recombination to mutation ratio (r/m) and the number of K-loci per lineage, adjusted by the lineage diversity (median recombination-free mutational pairwise distance, MMD)

A)   **B)**

K-loci structural variation

Known K-phenotypes account for only 34% of the numerous K-loci identified in this study, with these phenotypes sporadically distributed across the K-loci phylogeny (Fig. 5). Many K-loci correspond to deep ancestral branches that likely represent distinct K-types. In total, there were 229 region 2 capsular gene clusters (>70% amino acid AA sequence identity within clusters), of which 48% were annotated as "hypothetical protein", demonstrating considerable unexplored capsular-determining gene variation. The eight *kps* genes in G2 K-loci formed one major gene cluster each. Only six of the G2 K-loci contained a *kps* gene in a separate divergent cluster for at least one of the *kpsM, kpsT, kpsS* and/or *kpsC* genes, which are important in forming the biosynthesis-export complex[38]. Nine K-loci feature an atypical G2 locus structure that has not been previously reported, where region 2 is outside of regions 1 and 3 (Supplementary Figure 3). Although the atypical K-locus organisations are relatively rare in BSIs (<3.5%), they were spread across the species phylogeny and found in phylogroups A, B2, D and F. There were also sizable clusters of atypical loci in major *E. coli* BSI lineages: CC69 (KL13, n=84/449), CC131 (KL44, n=25/631), CC73 (KL44 n=20/981), CC59 (KL13 n=14/93). A Norwegian BSI isolate with the atypical K-locus KL73 was confirmed to be K+ but did not react with known K-antisera.

Unlike in G2, the diverse *kps* genes in G3 form two major gene clusters delineating the G3-A and G3-B subtypes (Fig. 5B). No G3 *kps* genes clustered with G2 *kps* genes. G3-A and most of G3-B share the five region 2 gene clusters *wsaE* and *rmlBDAC*. Meanwhile, K11, KL66, K19, KL65 and KL75 loci also have divergent and unique region 2 gene sets. K19, KL65, and KL75 are extremely divergent K-loci that do not share any gene clusters with G2, other G3, or each other, except for the 7th *kpsS* gene cluster (*kpsS*_7) between KL65 and KL75. K19 was observed in phylogroup A and shares no *kps* gene clusters with G2, KL66 has previously been classified as G3, and G3 has been suggested to be divergent G2 K-loci elsewhere[10,39]. Therefore, we denote these three loci as G3-C to G3-E.

317   **A)**

332   **B)**

K-loci diversification and gene mobility

The genomic survey of G2 and G3 K-loci allowed us to interrogate the mechanisms that may
have generated this considerable diversity. The proportion of unique K-loci sequences (at least
1bp difference) with one or more insertion sequences (IS) was 28.2% (1411/4996). While K1
was only observed with an IS once (n=1/692), K5 always had at least one IS (n=706). IS1 and
IS3 were the most common of the ten IS families observed in the K-loci collection. Importantly,
IS were observed overlapping with capsular coding sequences (CDS) in 17 K-loci and in nine of
these, the IS carried a putative capsule gene in Region 2 as cargo.

The K-locus KL6 (K-type K5) is one of three closely related K-loci based on gene presence-
absence patterns (after exclusion of the IS elements). The KL177 locus differs from KL6 by the
loss of *kfiD*; it was rare and only observed in carriage (n=3). In KL91, an IS1 316 element had a
putative glycosyl-transferase family two protein (group 145) and a truncated *kfiC* within its
terminal inverted repeats (TIRs, Supplementary Figure 2A). This locus was observed four times
in BSIs and five times in carriage. An IS variant of the KL6 locus (KL6-1) seen in a single ST131
isolate had an additional putative transposase (group 240) and a fragment of the extended-
spectrum β-lactamase gene bla_{CTX-M} near the IS3 remnant seen in all the K5-like loci. The
bla_{CTX-M} and transposase gene were observed together in multiple plasmid types within CC131
(100% identity), suggesting that both genes may have moved into this K-locus from a plasmid
via homologous recombination with the existing IS in these K-loci. There were three more
examples of IS in a KL6 background without any alteration to the K-locus-related gene content,
each observed once in the collection used to populate the database, suggesting IS movement in
and out of KL6 is happening frequently.

There were four different K-loci related to K4 (KL29) with differing gene presence-absence
patterns when IS genes were excluded (Supplementary Figure 2B). The *kfoA, kfoB, kfoC,* and
kfoD genes are present in all five, and kfoF (gene-cluster name *udg*) and *kfoE* were only absent
in KL88 and KL111, respectively. KL29-1 is an IS variant of KL29 where *kfoB* is split into two
fragments and kfoD is contained within an IS element. These IS elements were all observed
between *kpsS* and *kfoC* and likely contributed to the different patterns of capsular-specific
genes within region 2 for this cluster of related K-loci. K4 (KL29) was the most common of these

loci in BSIs (n=54). Whilst IS variants of K5-like loci and K4-like loci are rare, their existence

gives us insight into how capsular diversification and gene exchange may be driven by IS

moving between K-loci. There were no IS observed in the atypical loci, suggesting other

mechanisms are also at play.

The median distance of the K-locus from serA in the chromosome was confirmed to be

144,833bp (IQR 38,022bp). Recently, G3-B K-loci have been observed in plasmids, which could

act as a vehicle for capsular mobility[10]. As G3-B are rare in BSIs (n=11), we observed just two

Norwegian isolates with G3-B K11 in multireplicon plasmids (IncFIA-IncFIB-IncY and IncFIA-

IncY), and not in the chromosome. One of the isolates had K11 mobilised on a plasmid with

multiple resistance genes: bla_{TEM-1} *dfrA14, mph(A), sul2, aph(3")-Ib and aph(6)-Id*. Additionally,

a single *E. coli* isolate from Oxfordshire (n=1/549) was typed as G3-B KL139 on the plasmid

and not in the chromosome.

Discussion

Extensive phenotypic and structural data generated over several decades have demonstrated
considerable diversity in the *E. coli* capsular antigens using clinical isolates. Nevertheless,
systematic cataloguing of capsular genetic diversity in contemporary disease is essential to
further our understanding of the epidemiology of K-types, in particular with the increasing
infection burden of extraintestinal pathogenic *E. coli.* Here, we have shown that the diversity of
G2 and G3 K-loci found in BSIs far exceeds the number of the currently known G2 and G3
phenotypic capsular types. Furthermore, this diversity has major clinical implications, with
observed differences in K-type prevalence by isolation source and geographical location, in
addition to variation in the estimated invasive potential of K-types across different genetic
backgrounds. We determined that G2 and G3 capsules are present in the majority of ExPEC
infections across diverse settings. Specifically, K1 and K5 are the most common causes of UTIs
and BSIs. Although these two types are also the most common G2/G3 K-types in LMIC
neonatal disease, a significant fraction of these infections are caused by non-G2-G3, unlike in
high-resource settings. These particular findings have implications for the development of
preventive strategies. Of note, *in silico* typing of the *wzy*-dependent group 1 and group 4
capsules is a critical remaining knowledge gap to understand ExPEC disease in resource-
limited settings. There is a paucity of published ExPEC genomic data from systematic
epidemiological studies conducted in resource-limited regions of the world that sequencing
efforts have neglected. Although at present the existing data represent only a couple of LMICs,
our results clearly suggest that capsular epidemiology differs significantly from high-resource
settings for at least vulnerable neonates, suggesting prioritisation of future sampling efforts to
generate region-specific representative data similar to that for pneumococcal disease [40–42].
However, by screening a published database of assemblies created from all data deposited in
the sequence read archive (SRA) pre-2018[36], we were able to represent K-loci in the database
from 69 countries, including 31 countries from Africa, Asia and Oceania. The G2-G3 K-loci
repertoire observed in LMICs was well represented by the G2-G3 database, even if the exact
prevalence of G2-G3 K-types varies.
414

The role of capsules in pathogenesis has long been appreciated across bacterial species[1,43].
Whilst the study of *E. coli* capsules has stalled more recently, previous research efforts have
already experimentally demonstrated the virulence associated with most of the common *E. coli*
capsular types (e.g. K1, K2, K5, K52, K92 and K100) using either human immunological assays

or murine models[44–49]. Estimating the relative invasive potential allowed us to put these

experimental findings into a wider context by ranking the capsular types in terms of their

propensity to be found in BSIs, given the exposure frequency in asymptomatic colonisation. The

results suggest that the high frequency of the widely studied K1 and K5 types in disease is, at

least in part, a product of greater opportunistic spillover into vulnerable hosts. However, our

estimates additionally indicate that there are multiple K-types that have a greater ability to cause

an infection, given their ranked invasiveness. For example, K52 and K14, which are found in

multiple lineages, including the global MDR lineages CC69 and CC131, had the highest

estimates of invasiveness and subsequently ranked 3rd and 4th in BSI prevalence despite

rarely being seen in carriage samples in the UK and France (<2.5%). K1 has previously been

reported to be found across multiple lineages[46], and whilst the estimated invasive potential of K1

was not top-ranked, the ST95 lineage ranked 4th in the lineage random effects estimates,

suggesting the lineage is playing a key role in progression to bloodstream infections; this is

concordant with the many reported virulence factors found in this lineage[50,51]. In summary, our

results provide in this regard impetus for reinstating phenotypic capsular typing for this species

and renewed interest for experimental studies of virulence that could further disentangle the

contributions of capsules versus lineages towards invasiveness.

The development of ExPEC vaccines promises to improve public health by reducing the burden

of invasive disease. Still, their potential is complicated because many *E. coli* are commensal,

and some are considered beneficial to human health[52]. Therefore, vaccines must avoid

targeting a major constituent of the gut microbiota and broad *E. coli* sterilising immunity. This

requires a greater understanding of the differences between predominantly commensal

genotypes and successful ExPECs, as well as the pathogenic potential of the latter. K-types

with high estimated invasive potential are obvious vaccine targets due to both their capacity to

cause disease and because the removal of such types from the gut flora is less likely to affect

key *E. coli* commensals or have the potential for large replacement in carriage and disease as

other colonisers fill the vacated niche. While ExPEC vaccines have been under development

since the 1980s, only a few have been licensed. Whole-cell, O, H, K, and O-conjugates have all

undergone clinical trials[53]. Although evidence of K-autoreactivity is limited, mimicry of host

glycobiology may explain why anti-K antibodies are not strongly induced in vaccination or

disease[53]. Nonetheless, increased genomic data and expanded O-typing have contributed to

the increased development of subunit-based vaccines rather than whole-cell vaccines in recent

years[6,54].

Efforts to quantify the invasive potential of different K-types have been hindered by the scarcity

of *E. coli* colonisation data, which we overcame by building on recent breakthroughs in high-

resolution genotyping of pathogens from shotgun metagenomics[23]. Specifically, we leveraged

microbiome data from a large-scale UK infant-mother cohort[34,55] to survey asymptomatic *E. coli*

carriage. Using infant carriage to represent general colonisation is one limitation of this

approach. However, as healthy full-term babies acquire *E. coli* from family members and their

surroundings during their first year of life, reflected by the strain-sharing of the mother and the

baby[23,56], this suggests that the isolates seen in the infant population likely represent the

commensals circulating in the population more generally. Furthermore, we found no significant

differences in the overall K-type composition between the UK infant-mother collection and

French adults. K1 and CC10 were the only K-type and lineage with a significantly higher

prevalence in the French collection. If these two differences in carriage were due to the different

age-groups sampled, the relative invasive potential could be overestimated for K1 and CC10 in

our analysis; this, in fact, would not alter our conclusion that high K1 prevalence in carriage

influences the high prevalence in disease and that other lesser studied capsular types top the

invasiveness rankings. Despite differences in the sampling time period (2014-2017 vs. 2010),

sequencing approach (metagenomic vs. single colony sequencing) and geographical location,

the two carriage populations are similar, suggesting that there is limited age structure to human

E. coli colonisation in this geographical region. Whilst here we are currently limited to UK data

for which representative snapshots of both carriage and disease have been sampled and

sequenced, it has been shown that estimates of invasive potential have temporal and

geographical stability for other species, as this is considered a fixed trait of the capsule structure

independent of when and where matched datasets were isolated.[57]

Given that we observed some age and sex differences in epidemiology, the invasive potential

may vary in specific patient groups. The estimates reported in this manuscript represent the

average estimated relative invasive potential in BSIs across all age groups. However, 74% of

BSIs are in elderly patients of greater than 59 years, and so the estimates are likely to better

represent this important high-risk age group. Limiting the data to only elderly adults aged 59

years or older had a negligible effect on the rank order but, as expected, increased uncertainty

in the confidence intervals of all the K-type estimates. There was insufficient data from elderly

adults alone to estimate the relative invasive potential for four capsular types (KL30, K4, KL13,

KL70). The only other notable difference was that K12 moved up four places in the rank order

for the estimates using only elderly adults. It may thus represent a K-type that either requires a
more vulnerable population or circulates more commonly in older demographics, which were not
captured by the infant-mother carriage cohort. This further highlights how systematic population-
based K-type screening paired with high-quality metadata can advance understanding of any
potential age and sex-specific epidemiology of ExPEC infections. As further colonisation data is
generated alongside additional BSI metadata, there is potential for future meta-analyses across
countries that would increase the power to estimate the relative invasive potential of K-types in
different groups and reduce uncertainty around the point estimates.
495
Hard-to-treat infections could also conceivably be overrepresented in BSI isolates due to an
increased opportunity to progress to a systemic infection and influence estimates of invasive
potential. To account for this, we tested the association between the lineage random effects and
the proportion of UK BSI isolates per lineage that were either phenotypically MDR (EUCAST
v15) or bla_{CTX-M} positive. There was no correlation with the MDR proportion (R^2 = 0.029, p =
0.79), and when the CC131 C2 outlier was excluded, there was also no correlation with the
bla_{CTX-M} proportion (R^2 = 0.036, p = 0.74). Furthermore, when including the bla_{CTX-M} proportion
per lineage in an alternative mixed model, this covariate was not significant, and the only
resulting difference was that the CC131 C2 lineage ranking fell one position (behind CC12).
Finally, to further assess its robustness, we applied our model to a pneumococcal collection that
had previously been used to assess invasive potential [58] and reproduced the general rank order
of invasiveness by others, which includes capsules since long established to be the most
virulent for this bacterium[17,57,58].
509
Currently, there are over twice as many recognised O-serogroups as K-types[53]. Yet, we
observed a greater diversity of K-loci from G2 and G3 than O-loci in most dominant ExPEC
lineages. This result was obtained despite the conservative 70% sequence identity threshold
used here to define members of the same gene cluster compared to other typing schemes
[10,13,15]. Even greater diversity is likely to be discovered with further investigation into the genetic
determinants and delineation of serogroups. As little as a single base pair difference has been
seen in capsule-determining glycosyl-transferases of other species[59]. Indeed, we observe
multiple serotypes with the same capsular genes with high-sequence identities. These include
the K13 and K23 reference phenotypes that are both typed as KL21. They have previously been
reported to belong to a serogroup, along with K20, which has replaced one gene relative to K13
and K23[60]. When comparing K13 (NCTC9022, ERR999921) and K23 (NCTC10430,

ERR968281), there were only two non-synonymous changes in a region 2 gene, *vatD,* that

encodes an acetyltransferase. This putative determinant needs an in-depth phenotypic

validation to allow full genomic discrimination between them. The G3 phenotypes K54 and K96,

also share a set of capsular genes and are typed as KL36. Region 2 in these references (K96

MG736915, K54 CP9 ESC_JB5109AA_AS)[61], differs most notably by one non-synonymous

change that resulted in missense for 9 AA and truncation of 8 AA at the end of the K96-07

encoding an alginate O-acetyltransferase. In addition to this, though, most KL36 in BSIs also

had a truncation of 6 AA at the start of the K96_07 alginate O-acetyltransferase protein, not

seen in either the K54 or K96 phenotyped reference genomes. Other related clusters of K-loci

which differ by a single region 2 gene or with gene truncations could also represent further

cross-reactive serogroups. Alternatives to traditional K-phenotyping are in development that

could discriminate between subtly different K-phenotypes and allow novel K-types to be

assessed more readily.[62]

The evolution of the *E. coli* G2 and G3 K-locus is also of considerable interest *per se*, given the

fundamental biological role of the capsule and the complexity of its biosynthesis process. We

observed that a specific subgroup of G2 K-loci were found to be undergoing atypical

diversification of the K-locus, one of which had an invasiveness OR of significantly above one,

showing that atypical K-loci can also be of clinical importance. The divergent *kps* genes seen in

atypical K-loci may increase the opportunity for cross-species capsular gene exchange, and

their evolution warrants additional study. We were able to demonstrate an association between

estimated recombination to mutation rate and the observed capsule diversity per genetic

lineage, which suggests that the overall tendency of homologous recombination across the core

chromosome closely reflects the rate at which capsule switches occur via horizontal gene

transfer, influencing the K locus. Whilst earlier work detected the acquisition of the K1 capsule

by genetic lineages across several phylogroups over centuries[46], here we demonstrate that a

similar process has influenced the spread of most of the successful and invasive capsule types.

Notably, the capsule repertoire of a genetic lineage can grow rapidly by successful acquisitions

of new capsule types that expand in the population, whilst the O and H loci remain unchanged,

as demonstrated by the CC131 C1 and C2 subclades. The ability to diversify the capsule locus

for two major MDR lineages (CC69 and CC131) may have facilitated their rapid expansion in

BSIs in the 21st century.[24,27,28] We further discovered that IS elements are common within the K

loci and are likely contributing to the diversification of the polysaccharide composition of

capsules by importing genes into region 2, warranting deeper functional investigation of these

evolutionary processes. This appears to be a unique feature of *E. coli* G2 and G3 capsules;

whilst IS-elements have been reported in other species like *Klebsiella pneumoniae*[13,15], they

could be completely removed from the typing scheme as they were less common and purely

intergenic.

Taken together, our study provides further evidence for the need for improved understanding of

K-types and renewed experimental investigation to allow the development of strategies to

effectively control ExPEC disease.

Methods

Data

We used a published pangenome analysis of ~7,500 high-quality *E. coli* genomes to determine that the capsular gene *kpsF* was consistently annotated and predictive of G2 capsule presence [37]. We subsequently downloaded all *kpsF*-positive (0.9 kmer-ID threshold) *E. coli* in a published searchable collection of 661-thousand bacterial assemblies (n=11,623)[36]. For G3, we additionally screened the 661K database for all *kpsM*-positive assemblies (0.9 kmer-ID threshold, n=853) using the G3-A and G3-B *kpsM* alleles from K96 and K11, respectively, as *kpsM* is more divergent in G3. We supplemented these genomes with data from large published *E. coli* BSI longitudinal genomic collections from Norway (2002-2017, n=3,254, 60% hybrid assemblies)[27,63] and the UK (2001-2018 n=2,219)[24], and a collection of infant and mother *E. coli* carriage assemblies from the UK babybiome study (n=997, available from https://zenodo.org/records/14000489)[23,34], and two one-health *E. coli* studies from the UK (n=405) and USA (n=2948)[64,65]. Genomes with a known K phenotype were sourced for 24 different K-types from GenBank, the NCTC project[66] and Enterobase[67]. The NCTC reference strains (accession PRJEB6403) are maintained as preserved strains that can be obtained from the National Collection of Type Cultures, UK. K-loci were initially extracted from 21,802 assemblies using an *in-silico* PCR (https://github.com/simonrharris/in_silico_pcr) for known K-loci boundaries, i.e. *kpsF-kpsM* or *kpsM/D-kpsS*. PCR-negative K-loci were then manually extracted from assemblies that had been annotated with one or more *kps* genes.

K-loci

Extracted K-loci with unknown bases were excluded, and the K-loci were filtered down to 4,996 unique sequences with at least 1bp difference. These unique K-loci were annotated with Prokka[68] and analysed with Panaroo[69] to consistently annotate K-loci gene clusters with a conservative 70% family identity threshold. The gene cluster names were updated using the capsular-specific reference annotations to reflect the literature where possible. This resulted in an initial 225 gene absence patterns, excluding insertion elements (IS), which are arbitrarily numbered KL1-225. IS elements were identified from the annotations using ISEscan[70]. These 225 sequences were pruned to remove K-loci with redundant patterns due to misannotation,

paralogs, non-capsular genes, and incomplete K-locus remnants, leaving 90 curated K-loci in
the final K-loci database. K-loci from complete genomes, long-read/hybrid assemblies and
sequences containing the fewest available IS were preferentially included as the database
reference. The database was formatted for Kaptive3 [26], with IS annotations removed.
Unpublished data from European disease (n=1,592) and carriage from underrepresented
regions in Asia and Africa (n=10,085) were screened to determine that no dominant K-types had
been missed.
599
Assemblies (n=8,473) from published genomic collections [23,24,28,30–32,34,35,71,72] were K-typed
using Kaptive version 3.0.0b5, and this G2-G3 database, which is available at
https://github.com/rgladstone/EC-K-typing. Untypeables with three or fewer essential *kps* genes
were designated absent for G2-G3 K-loci. The assignment of chromosome or plasmid was
available for hybrid assemblies from Norway and Oxfordshire[29,63]. These were used to
determine if any K-loci were observed in plasmids in these BSI collections.
606
The relatedness of K-loci was assessed for G2 and G3 separately using the pairwise mash
hash distance of the K-locus sequences converted to a proportion 1-(n/1000), which gives
greater resolution than gene presence-absence but still captures core and accessory variation[73].
These distances were used to create Neighbour-joining phylogenies in the R v4.4.1 package
ape 5.8 and visualised in Phandango.net[74] using the following input files
https://github.com/rgladstone/EC-K-typing/tree/main/phandango.

Phenotypic confirmation

One hundred and fifty Norwegian BSI isolates were selected for phenotypic K-typing; these
were selected to represent imperfect matches to K-loci with known phenotypes (n=71), K-loci
where a phenotypic reference genome was not available (n=40) and isolates which were kps-
negative (n=39) to distinguish between G1-G4 and potentially acapsular isolates. K-phenotyping
was carried out by the Staten Serum Institute using reference capsular antisera. These data
were used to confirm phenotypes assigned in the K-typing database and to determine if K-loci
without a known K-phenotype expressed a putatively novel capsule using a positive precipitate
reaction with Cetavlon but negative with known K antigens.

E. coli carriage assemblies from metagenomic data

E. coli assemblies were extracted from metagenomic data from the UK babybiome data using a computational approach described in a previous study[72] to provide an *E. coli* gut colonisation dataset[34,75]. The sequencing read data was first pseudo-aligned against a diverse reference database constructed from the 661,000 assemblies study[36] (available from https://zenodo.org/records/7736981) with Themisto[76]. The alignments were then processed with mSWEEP and mGEMS[77,78] to assign each sequencing read to a bacterial species. Next, the reads assigned to *E. coli* were pseudo-aligned with Themisto against an *E. coli* database (https://zenodo.org/records/12528310) and processed again with mSWEEP and mGEMS to obtain assignments of the sequencing reads to *E. coli* PopPUNK lineages[79]. The resulting assignments ('bins') were quality controlled with demix_check (https://github.com/harry-thorpe/demix_check) and bins with scores 1 or 2 were retained (n=1,402). Reads belonging to the 1,402 bins were assembled with Shovill (https://github.com/tseemann/shovill), and small contigs <5000bp were discarded before K-typing. The assemblies are available at https://zenodo.org/records/14000489. As this collection sampled individuals within a family (mother and infant) multiple times during the first year of life, the isolates were deduplicated (n=997/1,402), allowing only one lineage representative with the same K-type per family. Mothers accounted for 67/997 of the isolates and infants between 6 months and 1 year old accounted for one third of the deduplicated set. When both a typeable and untypeable isolate were observed within a family for a particular lineage, we preferentially selected the K-typed isolate, as they are likely to be of the same strain but with a higher quality assembly; this accounts for the fact that lower coverage assemblies limit K-type detection.

Relative invasive potential

Lineages were defined based on core and accessory distances using PopPUNK[79]. Each lineage is named after the representative sequence type for each popPUNK lineage and described as a clonal Complex (CC), as each lineage contains multiple STs. To avoid a temporal bias whilst estimating the relative invasive potential, due to differences in collection years between BSI (2001-2017) and carriage (2014-2017), we excluded BSIs from 2001-2002 from the analysis to remove a known expansion of the CC69 and CC131 lineages, which later reached a stable equilibrium population frequency by 2003. Furthermore, we tested for a difference in proportions for each lineage and K-type between the 2003-2013 and 2014-2017 periods using two-sided Fisher's exact tests and adjusted for multiple testing. Only CC393 exhibited a significant

difference between the periods that could introduce bias. The K-loci, lineage information, and

the source of each isolate (infection/carriage) were input for modelling the relative invasive

potential of K-types and lineages using a generalised mixed model approach[23,24,28,34]. The model

included the isolation source as a binary outcome variable, the K-loci indicator variable as a

fixed effect (constant for each isolate) and the lineage indicator variable as a random effect.

Untypeable (*kps*-negative genomes or rare loci) was set as the reference category for K-loci.

Data were filtered to include only K-loci found in more than 20 isolates, with at least 5 isolates in

each infection and carriage group. The model was fitted in R using the glmer-function in the

lme4-package version 1.1.35.5[80]. The age of BSI patients, the likelihood that a strain was CTX-

M positive, and an increase in BSI prevalence of CC393 between 2002-2013 and 2014-2017

were possible confounders, the model was run four additional times: 1) BSAC restricted to

adults only n=1550/2036, 2) BSAC elderly adults only n=1202/2036, 3) BSAC with CC393

subsampled in 2003-2013 down to the same proportion as 2014-2017 of 0.02 n=2008/2036, 4)

adjusting for the CTX-M prevalence of each lineage in BSIs. We further assessed whether the

infant-mother metagenomic carriage data had significantly different K-epidemiology to a healthy

adult carriage whole genome collection [35] sampled in France in 2010, using a nonparametric

test of independence in R package coin v1.4-3 for the K-loci and lineages included in the

invasive potential model, and a comparison of proportions for each individual K-type and lineage

included in our model between these two carriage collections with the "BH" method for adjusting

for multiple testing. The model was also applied to a previously published pneumococcal

dataset for assessing invasive potential[17,58], leveraging the availability of paired carriage and

disease collections from two countries included in the model as a fixed effect. This multi-country

approach increased the sample size to 1,415 carriage isolates and 1,081 disease isolates.

https://github.com/rgladstone/EC-K-typing/tree/main/invasiveness/pneumo_example.

Lineage analysis

The top 10 PopPUNK[79] lineages were mapped against a corresponding ST reference, aligned,

and recombination removed with Gubbins[81,82]. The recombination over mutation ratio (r/m) per

lineage was estimated with Gubbins, and the median pairwise recombination-free mutational

distance (MMD) for each lineage was calculated using pairSNP[83]. The Pearson correlation

between r/m and the K-locus count per lineage, with adjustment for lineage diversity, using the

MMD, was calculated in R v4.4.1 base corr.test for the top 10 lineages with >95% G2-G3

capsules. For dating analysis, recombination-free phylogenies for CC69 and CC131 using

Norwegian and UK BSI data[24,27] were created with Gubbins v3.4[82] using SKA2[84] and dated with

the BactDating[85] ARC model with a 10,000,000 MCMC chain in three replicates and one with

randomised tip dates. The effective sampling size was >200, the Gelman statistic for

convergence was ~1, and the true date models were better than the random date models. The

resultant phylogenies were visualised in microreact[86]. To characterise the diversity of K-loci

within a lineage, we used Simpson's diversity index (SDI 1-D), which measures the relationship

between the number of "species" (here we use either K-loci or lineages), termed richness, and

individuals within each "species", termed evenness. O:H-typing was performed with SRST2[6].

Differences between proportions were tested with Fisher's (when any n<5) or Chi-squared

(when all n>5).

Acknowledgements

We thank our collaborators forming The Norwegian E. coli BSI Study Group: Nina Handal (Akershus University Hospital), Nils Olav Hermansen (Oslo University Hospital, Ullevål), Anita Kanestrøm (Østfold Hospital), Hege Elisabeth Larsen (Nordland Hospital), Paul Christoffer Lindemann (Haukeland University Hospital), Iren Høyland Löhr (Stavanger University Hospital), Åshild Marvik (Vestfold Hospital), Einar Nilsen (Molde Hospital and Ålesund Hospital), Marcela Pino (Oslo University Hospital, Rikshospitalet), Elisabeth Sirnes (Førde Hospital), Ståle Tofteland (Sørlandet Hospital), Kyriakos Zaragkoulias (Nord-Trøndelag Hospital Trust). We also thank Dr Kat Holt and Dr Kelly Wyres, who kindly advised us in maximising the database's utility with the Kaptive tool. Finally, we thank Susanne Jespersen and Marie Vilborg Jacobsen for their efforts in K-typing 150 isolates supported by the Gates Foundation.

Declaration of interests

The authors declare no competing interests

Inclusion and ethics statement

This publication used published genomic collections and metadata.

Supplementary

Supplementary Figure 1. K-loci in UK BSIs A) K-loci by sex B) K-loci per age group C) K-loci per age group by sex

Supplementary Figure 2. Gene presence and absence for A) the K5-like loci and B) K4-related loci

Supplementary Figure 3. Genetic architecture of atypical G2 K-loci

Supplementary Data - isolate metadata, database details, phenotypic data

Supplementary Figure 1. K-loci in UK BSIs A) K-loci by sex B) K-loci per age group C) K-loci per

 age group by sex

Supplementary Figure 2. Gene presence and absence for A) the K5-related loci and B) the K4-related loci. Genes were clustered across

the K-loci DB with a 70% ID threshold. Region 1 and 3 *kpsF-kpsM* (green), Region 2 containing genes determining the capsular type

(purple), and putative capsular genes (pink). IS genes and other non-capsular genes are included here (other). When the capsular-

specific gene name in the literature applies to a gene found in multiple capsular types across the database, the generic gene cluster

name is also given. Putative and known functions are shown in brackets.

A)

B)

Supplementary Figure 3. Genetic architecture of atypical G2 K-loci

The conserved Regions 1 and 3 genes are light green, with rarer gene clusters in darker green. Region 2 genes observed in known K-

types are in yellow, and those shared between atypical K-loci are in red. Genes only seen in one locus are blue. The top *E. coli* blast

match is shown in brackets for unannotated gene clusters.

References

1. Mba, I. E. *et al.* Vaccine development for bacterial pathogens: Advances, challenges and

prospects. *Trop. Med. Int. Health* **28**, 275–299 (2023).

2. Murray, C. J. L. *et al.* Global burden of bacterial antimicrobial resistance in 2019: a

systematic analysis. *Lancet* (2022) doi:10.1016/S0140-6736(21)02724-0.

3. Whitfield, C. Biosynthesis and assembly of capsular polysaccharides in Escherichia coli.

Annu. Rev. Biochem. **75**, 39–68 (2006).

4. Sussman, M. *Escherichia Coli: Mechanisms of Virulence*. (Cambridge University Press,

Cambridge, England, 1997).

5. Lin, H., Paff, M. L., Molineux, I. J. & Bull, J. J. Therapeutic Application of Phage Capsule

Depolymerases against K1, K5, and K30 Capsulated E. coli in Mice. *Front. Microbiol.* **8**,

2257 (2017).

6. Ingle, D. J. *et al.* In silico serotyping of E. coli from short read data identifies limited novel

O-loci but extensive diversity of O:H serotype combinations within and between pathogenic

lineages. *Microb Genom* **2**, e000064 (2016).

7. Whitfield, C. Structure and Assembly of Escherichia coli Capsules. *EcoSal Plus* **3**, (2009).

8. Hong, Y., Cunneen, M. M. & Reeves, P. R. Two extremely divergent sequence forms of the

genes that define Escherichia coli group 3 capsules suggest a very long history since their

common ancestor. *FEMS Microbiol. Lett.* **366**, (2019).

9. Clark, J. R. & Maresso, A. M. Comparative Pathogenomics of Escherichia coli: Polyvalent

Vaccine Target Identification through Virulome Analysis. *Infect. Immun.* **89**, e0011521

(2021).

10. Hong, Y., Qin, J., Forga, X. B. & Totsika, M. Extensive Diversity in Escherichia coli Group 3

Capsules Is Driven by Recombination and Plasmid Transfer from Multiple Species.

Microbiol Spectr **11**, e0143223 (2023).

11.   Holt, K. E., Lassalle, F., Wyres, K. L., Wick, R. & Mostowy, R. J. Diversity and evolution of

surface polysaccharide synthesis loci in Enterobacteriales. *ISME J.* **14**, 1713–1730 (2020).

12.   Mostowy, R. J. & Holt, K. E. Diversity-generating machines: Genetics of bacterial sugar-

coating. *Trends Microbiol.* **26**, 1008–1021 (2018).

13.   Wyres, K. L., Cahill, S. M., Holt, K. E., Hall, R. M. & Kenyon, J. J. Identification of

Acinetobacter baumannii loci for capsular polysaccharide (KL) and lipooligosaccharide

outer core (OCL) synthesis in genome assemblies using curated reference databases

compatible with Kaptive. *Microb Genom* **6**, (2020).

14.   Kunduru, B. R., Nair, S. A. & Rathinavelan, T. EK3D: an E. coli K antigen 3-dimensional

structure database. *Nucleic Acids Res.* **44**, D675–81 (2016).

15.   Wyres, K. L. *et al.* Identification of Klebsiella capsule synthesis loci from whole genome

data. *Microb Genom* **2**, e000102 (2016).

16.   Yang, S. *et al.* Genetic diversity of K-antigen gene clusters of Escherichia coli and their

molecular typing using a suspension array. *Can. J. Microbiol.* **64**, 231–241 (2018).

17.   Løchen, A., Truscott, J. E. & Croucher, N. J. Analysing pneumococcal invasiveness using

Bayesian models of pathogen progression rates. *PLoS Comput. Biol.* **18**, e1009389 (2022).

18.   Corander, J. *et al.* Frequency-dependent selection in vaccine-associated pneumococcal

population dynamics. *Nat Ecol Evol* **1**, 1950–1960 (2017).

19.   Colijn, C., Corander, J. & Croucher, N. J. Designing ecologically optimized pneumococcal

vaccines using population genomics. *Nat Microbiol* **5**, 473–485 (2020).

20.   Sleeman, K. L. *et al.* Capsular serotype-specific attack rates and duration of carriage of

Streptococcus pneumoniae in a population of children. *J. Infect. Dis.* **194**, 682–688 (2006).

21.   Jounio, U. *et al.* Genotypic and phenotypic characterization of carriage and invasive

disease isolates of Neisseria meningitidis in Finland. *J. Clin. Microbiol.* **50**, 264–273 (2012).

22.   Yazdankhah, S. P. *et al.* Distribution of serogroups and genotypes among disease-

associated and carried isolates of Neisseria meningitidis from the Czech Republic, Greece,

and Norway. *J. Clin. Microbiol.* **42**, 5146–5153 (2004).

23. Mäklin, T. *et al.* Strong pathogen competition in neonatal gut colonisation. *Nat. Commun.*

13, 7417 (2022).

24. Pöntinen, A. K. *et al.* Modulation of multi-drug resistant clone success in Escherichia coli

populations: a longitudinal multi-country genomic and antibiotic usage cohort study. *Lancet*

Microbe (2024) doi:10.1016/S2666-5247(23)00292-6.

25. Ojala, F. *et al.* Basic reproduction number for pandemic *Escherichia coli* clones varies

markedly and can be comparable to pandemic influenza viruses. *bioRxiv*

2024.05.08.593267 (2024) doi:10.1101/2024.05.08.593267.

26. Lam, M. M. C., Wick, R. R., Judd, L. M., Holt, K. E. & Wyres, K. L. Kaptive 2.0: updated

capsule and lipopolysaccharide locus typing for the Klebsiella pneumoniae species

complex. *Microb Genom* **8**, (2022).

27. Gladstone, R. A. *et al.* Emergence and dissemination of antimicrobial resistance in

Escherichia coli causing bloodstream infections in Norway in 2002–17: a nationwide,

longitudinal, microbial population genomic study. *The Lancet Microbe* **2**, e331–e341 (2021).

28. Kallonen, T. *et al.* Systematic longitudinal survey of invasive Escherichia coli in England

demonstrates a stable population structure only transiently disturbed by the emergence of

ST131. *Genome Res.* (2017) doi:10.1101/gr.216606.116.

29. Lipworth, S. *et al.* The plasmidome associated with Gram-negative bloodstream infections:

A large-scale observational study using complete plasmid assemblies. *Nat. Commun.* **15**,

1612 (2024).

30. Handal, N. *et al.* A comparative study of the molecular characteristics of human

uropathogenic Escherichia coli collected from two hospitals in Norway and France in 2019.

J. Antimicrob. Chemother. dkaf130 (2025).

31. Thänert, R. *et al.* Persisting uropathogenic Escherichia coli lineages show signatures of

niche-specific within-host adaptation mediated by mobile genetic elements. *Cell Host*

Microbe **0**, (2022).

32. Sands, K. *et al.* Characterization of antimicrobial-resistant Gram-negative bacteria that

cause neonatal sepsis in seven low- and middle-income countries. *Nat Microbiol* **6**, 512–

523 (2021).

33. Pearse, O. *et al.* High diversity of Escherichia coli causing invasive disease in neonates in

Malawi poses challenges for O-antigen based vaccine approach. *Commun. Med. (Lond.)* **5**,

298 (2025).

34. Shao, Y. *et al.* Primary succession of Bifidobacteria drives pathogen resistance in neonatal

microbiota assembly. *Nat. Microbiol.* **9**, 2570–2582 (2024).

35. Marin, J. *et al.* The Population Genomics of Increased Virulence and Antibiotic Resistance

in Human Commensal Escherichia coli over 30 Years in France. *Appl. Environ. Microbiol.*

88, e0066422 (2022).

36. Blackwell, G. A. *et al.* Exploring bacterial diversity via a curated and searchable snapshot of

archived DNA sequences. *PLoS Biol.* **19**, e3001421 (2021).

37. Horesh, G. *et al.* A comprehensive and high-quality collection of Escherichia coli genomes

and their genes. *Microb Genom* **7**, (2021).

38. Whitfield, C. & Roberts, I. S. Structure, assembly and regulation of expression of capsules

in Escherichia coli. *Mol. Microbiol.* **31**, 1307–1319 (1999).

39. Sande, C. & Whitfield, C. Capsules and Extracellular Polysaccharides in Escherichia coli

and Salmonella. *EcoSal Plus* **9**, eESP00332020 (2021).

40. Lo, S. W. *et al.* Pneumococcal lineages associated with serotype replacement and

antibiotic resistance in childhood invasive pneumococcal disease in the post-PCV13 era: an

international whole-genome sequencing study. *Lancet Infect. Dis.* **19**, 759–769 (2019).

41. Garcia Quesada, M. *et al.* Serotype distribution of remaining invasive pneumococcal

disease after extensive use of ten-valent and 13-valent pneumococcal conjugate vaccines

(the PSERENADE project): a global surveillance analysis. *Lancet Infect. Dis.* **25**, 445–456

(2025).

42. Maeda, H. & Morimoto, K. Global distribution and characteristics of pneumococcal

serotypes in adults. *Hum. Vaccin. Immunother.* **21**, 2469424 (2025).

43. Moxon, E. R. & Kroll, J. S. The role of bacterial polysaccharide capsules as virulence

factors. *Curr. Top. Microbiol. Immunol.* **150**, 65–85 (1990).

44. Buckles, E. L. *et al.* Role of the K2 capsule in Escherichia coli urinary tract infection and

serum resistance. *J. Infect. Dis.* **199**, 1689–1697 (2009).

45. Cross, A. S., Kim, K. S., Wright, D. C., Sadoff, J. C. & Gemski, P. Role of

lipopolysaccharide and capsule in the serum resistance of bacteremic strains of

Escherichia coli. *J. Infect. Dis.* **154**, 497–503 (1986).

46. Arredondo-Alonso, S. *et al.* Evolutionary and functional history of the Escherichia coli K1

capsule. *Nat. Commun.* **14**, 3294 (2023).

47. Merino, I. *et al.* Molecularly defined extraintestinal pathogenic Escherichia coli status

predicts virulence in a murine sepsis model better than does virotype, individual virulence

genes, or clonal subset among E. coli ST131 isolates. *Virulence* **11**, 327–336 (2020).

48. Mostafavi, S. K. S., Najar-Peerayeh, S., Mobarez, A. M. & Parizi, M. K. Characterization of

uropathogenic E. coli O25b-B2-ST131, O15:K52:H1, and CGA: Neutrophils apoptosis,

serum bactericidal assay, biofilm formation, and virulence typing. *J. Cell. Physiol.* **234**,

18272–18282 (2019).

49. Suerbaum, S., Friedrich, S., Leying, H. & Opferkuch, W. Expression of capsular

polysaccharide determines serum resistance in Escherichia coli K92. *Zentralbl. Bakteriol.*

281, 146–157 (1994).

50. Weissman, S. J. *et al.* Clonal analysis reveals high rate of structural mutations in fimbrial

adhesins of extraintestinal pathogenic Escherichia coli. *Mol. Microbiol.* **59**, 975–988 (2006).

51. Johnson, T. J. *et al.* Comparison of extraintestinal pathogenic Escherichia coli strains from

human and avian sources reveals a mixed subset representing potential zoonotic

pathogens. *Appl. Environ. Microbiol.* **74**, 7043–7050 (2008).

52. Wassenaar, T. M. Insights from 100 years of research with probiotic E. coli. *Eur. J.*

Microbiol. Immunol. (Bp.) **6**, 147–161 (2016).

53. Qiu, L. *et al.* Vaccines against extraintestinal pathogenic Escherichia coli (ExPEC):

progress and challenges. *Gut Microbes* **16**, 2359691 (2024).

54. Weerdenburg, E. *et al.* Global distribution of O serotypes and antibiotic resistance in

extraintestinal pathogenic Escherichia coli collected from the blood of patients with

bacteremia across multiple surveillance studies. *Clin. Infect. Dis.* **76**, e1236–e1243 (2023).

55. Shao, Y. *et al.* Stunted microbiota and opportunistic pathogen colonization in caesarean-

section birth. *Nature* **574**, 117–121 (2019).

56. Tonkin-Hill, G. *et al.* Enhanced metagenomics-enabled transmission inference with TRACS.

bioRxiv 2024.08.19.608527 (2024) doi:10.1101/2024.08.19.608527.

57. Brueggemann, A. B. *et al.* Clonal relationships between invasive and carriage

Streptococcus pneumoniae and serotype- and clone-specific differences in invasive

disease potential. *J. Infect. Dis.* **187**, 1424–1432 (2003).

58. Gladstone, R. A. *et al.* International genomic definition of pneumococcal lineages, to

contextualise disease, antibiotic resistance and vaccine impact. *EBioMedicine* **43**, 338–346

(2019).

59. Mavroidi, A. *et al.* Evolutionary genetics of the capsular locus of serogroup 6 pneumococci.

J. Bacteriol. **186**, 8181–8192 (2004).

60. Vann, W. F. *et al.* Serological, chemical, and structural analyses of the Escherichia coli

cross-reactive capsular polysaccharides K13, K20, and K23. *Infect. Immun.* **39**, 623–629

(1983).

61. Olson, M. A. *et al.* Bile salts regulate zinc uptake and capsule synthesis in a mastitis-

associated extraintestinal pathogenic Escherichia coli strain. *Infect. Immun.* **89**, e0035721

(2021).

62. Rutschmann, C. *et al.* DMB labelling for detection and analysis of capsular

polysaccharides. *Biochemistry* (2025).

63. Arredondo-Alonso, S. *et al.* Plasmid-driven strategies for clone success in Escherichia coli.

Nat. Commun. **16**, 2921 (2025).

64. Liu, C. M. *et al.* Using source-associated mobile genetic elements to identify zoonotic

extraintestinal E. coli infections. *One Health* **16**, 100518 (2023).

65. Ludden, C. *et al.* One Health Genomic Surveillance of Escherichia coli Demonstrates

Distinct Lineages and Mobile Genetic Elements in Isolates from Humans versus Livestock.

MBio **10**, (2019).

66. Dicks, J. *et al.* NCTC3000: a century of bacterial strain collecting leads to a rich genomic

data resource. *Microb. Genom.* **9**, mgen000976 (2023).

67. Zhou, Z., Charlesworth, J. & Achtman, M. HierCC: a multi-level clustering scheme for

population assignments based on core genome MLST. *Bioinformatics* **37**, 3645–3646

(2021).

68. Seemann, T. Prokka: rapid prokaryotic genome annotation. *Bioinformatics* (2014).

69. Tonkin-Hill, G. *et al.* Producing polished prokaryotic pangenomes with the Panaroo

pipeline. *Genome Biol.* **21**, 180 (2020).

70. Xie, Z. & Tang, H. ISEScan: automated identification of insertion sequence elements in

prokaryotic genomes. *Bioinformatics* **33**, 3340–3347 (2017).

71. Gladstone, R. A. *et al.* Emergence and Dissemination of Antimicrobial Resistance in

Escherichia Coli Causing Bloodstream Infections: A Nationwide Longitudinal Microbial

Population Genomic Cohort Study in Norway between 2002-2017. (2020)

doi:10.2139/ssrn.3645193.

72. Khawaja, T. *et al.* Deep sequencing of Escherichia coli exposes colonisation diversity and

impact of antibiotics in Punjab, Pakistan. *Nat. Commun.* (2024) doi:10.1038/s41467-024-

49591-5.

73. Ondov, B. D. *et al.* Mash: fast genome and metagenome distance estimation using

MinHash. *Genome Biol.* **17**, 132 (2016).

74. Hadfield, J. *et al.* Phandango: an interactive viewer for bacterial population genomics.

Bioinformatics **34**, 292–293 (2018).

75. Mäklin, T. *et al.* Geographical variation in colorectal and urinary tract linked cancer

incidence is associated with population exposure to colibactin-producing *Escherichia coli.*

Lancet Microbe (2024) doi:10.1016/69j.lanmic.2024.101015.

76. Alanko, J. N., Vuohtoniemi, J., Mäklin, T. & Puglisi, S. J. Themisto: a scalable colored k-

mer index for sensitive pseudoalignment against hundreds of thousands of bacterial

genomes. *Bioinformatics* **39**, i260–i269 (2023).

77. Mäklin, T. *et al.* High-resolution sweep metagenomics using fast probabilistic inference.

Wellcome Open Res. **5**, 14 (2021).

78. Mäklin, T. *et al.* Bacterial genomic epidemiology with mixed samples. *Microb Genom* **7**,

(2021).

79. Lees, J. A. *et al.* Fast and flexible bacterial genomic epidemiology with PopPUNK. *Genome*

Res. **29**, 304–316 (2019).

80. Bates, D., Mächler, M., Bolker, B. & Walker, S. Fitting linear mixed-effects models

Usinglme4. *J. Stat. Softw.* **67**, (2015).

81. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler

transform. *Bioinformatics* **25**, 1754–1760 (2009).

82. Croucher, N. J. *et al.* Rapid phylogenetic analysis of large samples of recombinant bacterial

whole genome sequences using Gubbins. *Nucleic Acids Res.* **43**, e15 (2015).

83. Tonkin-Hill, G. *Pairsnp-Cpp*. (Github).

84. Derelle, R. *et al.* Seamless, rapid, and accurate analyses of outbreak genomic data using

split k-mer analysis. *Genome Res.* **34**, 1661–1673 (2024).

85. Didelot, X., Croucher, N. J., Bentley, S. D., Harris, S. R. & Wilson, D. J. Bayesian inference

of ancestral dates on bacterial phylogenetic trees. *Nucleic Acids Res.* **46**, e134 (2018).

86. Argimón, S. *et al.* Microreact: visualizing and sharing data for genomic epidemiology and

phylogeography. *Microb Genom* **2**, e000093 (2016).

948